Shares of Acadia Pharmaceuticals (ACAD) popped over 25 percent this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis. Despite the pop, the company's stock still trades at nearly half of where it was last summer. Michael Kramer, portfolio manager at Mott Capital at Covestor, says the corner has been turned and it could soon regain those heights with a potentially favorable outcome from the FDA in early May. Kramer added that the shares could see an additional surge because 'a lot of people got short the stock ahead of this panel thinking it would ultimately not get a favorable outcome.' Kramer is also bullish on Alkermes (ALKS) , which saw its stock halved in January when its depression drug disappointed in a trial.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.